Clinical Trial Update: De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A trial update on de‑intensified radiation therapy with either cisplatin chemotherapy or nivolumab immunotherapy for early-stage HPV-positive oropharyngeal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basaloid Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Cancer
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-02